In last trading session, OncoSec Medical Incorporated (NASDAQ:ONCS) saw 1.02 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $3.73 trading at -$0.19 or -4.85% at ring of the bell on the day assigns it a market valuation of $7.65M. That closing price of ONCS’s stock is at a discount of -831.9% from its 52-week high price of $34.76 and is indicating a premium of 10.19% from its 52-week low price of $3.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.9 million shares which gives us an average trading volume of 277.87K if we extend that period to 3-months.
For OncoSec Medical Incorporated (ONCS), analysts’ consensus is at an average recommendation of a Hold while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.24 in the current quarter.
OncoSec Medical Incorporated (NASDAQ:ONCS) trade information
Upright in the red during last session for losing -4.85%, in the last five days ONCS remained trading in the red while hitting it’s week-highest on Tuesday, 11/22/22 when the stock touched $3.73 price level, adding 42.62% to its value on the day. OncoSec Medical Incorporated’s shares saw a change of -82.33% in year-to-date performance and have moved -5.09% in past 5-day. OncoSec Medical Incorporated (NASDAQ:ONCS) showed a performance of -59.65% in past 30-days. Number of shares sold short was 63230.0 shares which calculate 3.4 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $110.00 to the stock, which implies a rise of 96.61% to its current value. Analysts have been projecting $110.00 as a low price target for the stock while placing it at a high target of $110.00. It follows that stock’s current price would drop -2849.06% in reaching the projected high whereas dropping to the targeted low would mean a loss of -2849.06% for stock’s current value.
OncoSec Medical Incorporated (ONCS) estimates and forecasts
The company is estimating its revenue growth to increase by 17.20% in the current quarter and calculating 24.00% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 39.40% during past 5 years.
OncoSec Medical Incorporated is more likely to be releasing its next quarterly report on December 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
OncoSec Medical Incorporated (NASDAQ:ONCS)’s Major holders
Insiders are in possession of 55.94% of company’s total shares while institution are holding 14.02 percent of that, with stock having share float percentage of 31.83%. Investors also watch the number of corporate investors in a company very closely, which is 14.02% institutions for OncoSec Medical Incorporated that are currently holding shares of the company. Avidity Partners Management, LP is the top institutional holder at ONCS for having 2.94 million shares of worth $2.18 million. And as of Jun 29, 2022, it was holding 7.48% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 0.73 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 1.86% of outstanding shares, having a total worth of $0.54 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 0.44 million shares of worth $0.32 million or 1.11% of the total outstanding shares. The later fund manager was in possession of 0.29 million shares on Jun 29, 2022, making its stake of worth around $0.21 million in the company or a holder of 0.73% of company’s stock.